Drugs Made In America Acquisition Corp. (DMAA)
NASDAQ: DMAA · Real-Time Price · USD
10.56
0.00 (-0.05%)
At close: Apr 28, 2026, 4:00 PM EDT
10.57
+0.01 (0.09%)
After-hours: Apr 28, 2026, 4:00 PM EDT
DMAA Statistics
Total Valuation
DMAA has a market cap or net worth of $356.05 million. The enterprise value is $356.38 million.
| Market Cap | 356.05M |
| Enterprise Value | 356.38M |
Important Dates
| Earnings Date | n/a |
| Ex-Dividend Date | n/a |
Share Statistics
DMAA has 33.72 million shares outstanding.
| Current Share Class | 33.72M |
| Shares Outstanding | 33.72M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | +2.00% |
| Owned by Insiders (%) | 1.19% |
| Owned by Institutions (%) | 63.69% |
| Float | 27.31M |
Valuation Ratios
The trailing PE ratio is 56.29.
| PE Ratio | 56.29 |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 59.99 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.03
| Current Ratio | 0.03 |
| Quick Ratio | 0.02 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -1.46% |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | -1.18% |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +4.97% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | +4.97% |
| 50-Day Moving Average | 10.48 |
| 200-Day Moving Average | 10.34 |
| Relative Strength Index (RSI) | 66.16 |
| Average Volume (20 Days) | 284,230 |
Short Selling Information
The latest short interest is 1.47 million, so 4.35% of the outstanding shares have been sold short.
| Short Interest | 1.47M |
| Short Previous Month | 17,252 |
| Short % of Shares Out | 4.35% |
| Short % of Float | 5.37% |
| Short Ratio (days to cover) | 7.55 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -2.82M |
| Pretax Income | 5.94M |
| Net Income | 5.94M |
| EBITDA | n/a |
| EBIT | -2.82M |
| Earnings Per Share (EPS) | $0.19 |
Balance Sheet
The company has $6,137 in cash and n/a in debt, giving a net cash position of $6,137 or $0.00 per share.
| Cash & Cash Equivalents | 6,137 |
| Total Debt | n/a |
| Net Cash | 6,137 |
| Net Cash Per Share | $0.00 |
| Equity (Book Value) | -7.26M |
| Book Value Per Share | -0.22 |
| Working Capital | -363,981 |
Cash Flow
| Operating Cash Flow | -539,187 |
| Capital Expenditures | n/a |
| Depreciation & Amortization | n/a |
| Net Borrowing | -900,000 |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
DMAA does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | n/a |
| Shareholder Yield | n/a |
| Earnings Yield | 1.67% |
| FCF Yield | n/a |
Analyst Forecast
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |